News

Bardoxolone methyl, which is currently in late Phase 2 trials, is an oral, antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the

The recall has been initiated by Abbott following an internal quality review, which detected the remote possibility of the presence of a small common beetle in the product

The Apposition II trial involved 80 patients and was conducted in 6 European countries, between December 2009 and June 2010, which compares the Stentys self-apposing stent with a

Menerba is an oral, botanically-derived estrogen receptor beta (ER-b) selective drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. With this

PNT2258 is an oligonucleotide therapeutic encapsulated within Marina Biotech’s proprietary Smarticles delivery technology. The Smarticles delivery technologywas developed by Novosom and acquired by Marina Biotech in July 2010.

The collaboration will explore the use of EyeGate’s iontophoresis technology, which is currently being studied in a Phase III trial with an anti-inflammatory product (EGP-437), to deliver RXi’s

Additionally, a pharmacokinetic study was presented, which investigated linagliptin in a special patient population with different degrees of renal impairment. Linagliptin belongs to the new class of DPP-4

RapID, developed in collaboration with ZyGem as a Lockheed Martin Technology innovation initiative, leverages the latest in microfluidic research and development to accelerate the DNA identification process essentially

Parexel will assist Lilly in bringing efficiencies to its clinical research studies to help meet Lilly’s development and commercialisation goals. The collaboration will allow Lilly to focus on